|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN)' Brain Cancer Vaccine Phase 2 Study to be Presented at Plenary Session of the 80th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
4/2/2012 9:51:38 AM
LEXINGTON, Mass., April 2, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Dr. Andrew Parsa, Professor in Residence, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract entitled, "A Phase 2 multicenter trial of autologous heat shock protein-peptide vaccine (HSPPC-96; vitespen) for recurrent glioblastoma multiforme (GBM) patients shows improved survival compared to a contemporary cohort controlled for age, KPS and extent of resection," at the 80th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Miami, Florida, April 14-18, 2012. Dr. Parsa's presentation will be given during Plenary Session II of the AANS meeting, which is scheduled for April 17, 2012 at 10:30 am ET.
|
|
|
|
|
|
|
|
|
|
|